Covaxin completes submission of documents for emergency use in Canada

Covaxin completes submission of documents for emergency use in Canada

Covaxin completes submission of documents for emergency use in Canada

While the manufacturers of the Covid-19 vaccine Covaxin have completed their submission to Canadian health authorities for emergency use, they have also stressed that the jab is the only one to have shown efficacy against the Delta variant in a controlled clinical trial.

Covaxin has been developed and manufactured in India by Bharat Biotech, which entered into an agreement with the American firm Ocugen for the North American market, and the latter established a presence in Canada through Vaccigen to facilitate the review process with Health Canada.

Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunisation in India, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomised, multicenter, phase 3 clinical trial.

In India, the monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha, citing information from the COVID-19 vaccine manufacturers.

“As communicated by the manufacturers, the monthly vaccine production capacity of Covishield is projected to be increased from 110 million doses per month to more than 120 million doses per month and the production capacity of Covaxin is projected to be increased from 25 million doses per month to around 58 million doses per month,” the minister said in a written reply.

With Canadian health authorities warning of the portents of a potential fourth wave in the country sparked by the Delta variant, he underscored the relevance of Covaxin in this context. In response to emailed queries, Inchausti said, “With the rapid spread of Covid-19, including its Delta variant, it is clear that additional vaccine options have the potential to help reverse this negative trend. Currently, there are no head-to-head studies between Covaxin and other Covid-19 vaccines. Covaxin is the only investigational Covid-19 vaccine to demonstrate, in a controlled clinical trial, efficacy against the Delta variant. (efficacy rate: 65.2%).”